Duyuru • Jun 30

Sarepta Therapeutics Announces FDA Acceptance Of Supplemental New Drug Applications For Amondys 45 And Vyondys 53 For Duchenne Muscular Dystrophy

Sarepta Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Applications (sNDAs) for AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) for the treatment of Duchenne muscular dystrophy (DMD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027. The sNDA submissions seek conversion of the accelerated approvals of AMONDYS 45 and VYONDYS 53 to traditional approvals. The applications are supported by data from the ESSENCE confirmatory study, as well as substantial published real-world evidence and the favorable and consistent safety profiles of both exon-skipping therapies. EXONDYS 51 (eteplirsen), AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) are exon-skipping therapies approved under the FDA’s accelerated approval pathway for patients with DMD who have mutations amenable to exon 51, exon 45 and exon 53 skipping, respectively. For more than a decade, Sarepta’s exon-skipping therapies have been used to treat over 1,800 amenable patients worldwide, from infants as young as 7 months to adults well into their 30s. In the Phase 3 ESSENCE study evaluating casimersen and golodirsen versus placebo, the primary endpoint was not met; however, numerical trends favored treatment. Additional post-hoc analyses were performed to evaluate heterogeneity challenges related to DMD progression and the impact of conducting ESSENCE during COVID-19. At week 96, treatment was associated with increased dystrophin expression and a consistent reduction in 4-step ascend decline across multiple analyses. The therapies were well tolerated over 144 weeks with no new safety signals observed, consistent with established clinical and real-world experience. Results from ESSENCE add to the available evidence for VYONDYS 53 and AMONDYS 45, including real-world studies demonstrating that treatment with VYONDYS 53 is associated with a 7.5 year delay in the need for nighttime ventilation and treatment with AMONDYS 45 is associated with a statistically significant slowing of lung function decline and a potentially meaningful benefit in the predicted time to use of a cough assist device. Across our PMO portfolio, real-world evidence indicates a multi-year benefit on survival, delays in time to loss of ambulation of 3 and 4 years, a substantial reduction in risk of reaching a left ventricular ejection fraction (LVEF) of less than 55%, and a significant reduction in emergency room and other hospital visits. EXONDYS 51 uses Sarepta’s proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion, or “skipping”, of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials. EXONDYS 51 has met the full statutory standards for safety and effectiveness and as such is not considered investigational or experimental. Hypersensitivity reactions, including bronchospasm, chest pain, cough, tachycardia, and urticaria have occurred in patients who were treated with EXONDYS 51. If a hypersensitivity reaction occurs, institute appropriate medical treatment and consider slowing the infusion or interrupting the EXONDYS 51 therapy. Adverse reactions in DMD patients (N=8) treated with EXONDYS 51 30 mg or 50 mg/kg/week by intravenous (IV) infusion with an incidence of at least 25% more than placebo (N=4) (Study 1, 24 weeks) were (EXONDYS 51, placebo): balance disorder (38%, 0%), vomiting (38%, 0%) and contact dermatitis (25%, 0%). The most common adverse reactions were balance disorder and vomiting. Because of the small numbers of patients, these represent crude frequencies that may not reflect the frequencies observed in practice. The 50 mg/kg once weekly dosing regimen of EXONDYS 51 is not recommended. The most common adverse reactions from observational clinical studies (N=163) seen in greater than 10% of patients were headache, cough, rash, and vomiting. Other adverse events may occur. VYONDYS 53 (golodirsen) uses Sarepta’s proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to bind to exon 53 of dystrophin pre-mRNA, resulting in exclusion, or “skipping,” of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials. Because of the effect of reduced skeletal muscle mass on creatinine measurements, creatinine may not be a reliable measure of kidney function in DMD patients. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting AMONDYS 45. Consider also measuring glomerular filtration rate using an exogenous filtration marker before starting AMONDYS 45. During treatment, monitor urine dipstick every month, and serum cystatin C and urine protein-to-creatinine ratio (UPCR) every three months. Only urine expected to be free of excreted AMONDYS 45 should be used for monitoring of urine protein. Urine obtained on the day of AMONDYS 45 infusion prior to the infusion, or urine obtained at least 48 hours after the most recent infusion, may be used. Alternatively, use a laboratory test that does not use the reagent pyrogallol red, as this reagent has the potential to cross react with any AMONDYS 45 that is excreted in the urine and thus lead to a false positive result for urine protein. If a persistent increase in serum cystatin C or proteinuria is detected, refer to a pediatric nephrologist for further evaluation. Adverse reactions occurring in at least 20% of patients treated with AMONDYS 45 and at least 5% more frequently than in the placebo group were (AMONDYS 45, placebo): upper respiratory infections (65%, 55%), cough (33%, 26%), pyrexia (33%, 23%), headache (32%, 19%), arthralgia (21%, 10%), and oropharyngeal pain (21%, 7%). Other adverse reactions that occurred in at least 10% of patients treated with AMONDYS 45 and at least 5% more frequently than in the placebo group were: ear pain, nausea, ear infection, post-traumatic pain, and dizziness and light-headedness. Other adverse events may occur.

Biotechs Sektör Büyümesi	14.79%
Gelir büyüme oranı	27.60%
Özkaynak getirisi	-8.95%
Net Marj	-6.93%
Son Kazanç Güncellemesi	30 Jun 2026

Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 26	1,974	-137	437	-719
31 Mar 26	2,184	65	467	0
31 Dec 25	2,198	-713	492	0
30 Sep 25	2,414	-272	527	945
30 Jun 25	2,482	-58	564	945
31 Mar 25	2,233	-248	564	0
31 Dec 24	1,902	235	558	0
30 Sep 24	1,640	122	526	0
30 Jun 24	1,505	47	518	0
31 Mar 24	1,403	17	498	0
31 Dec 23	1,243	-536	482	0
30 Sep 23	1,105	-691	471	0
30 Jun 23	1,003	-908	455	0
31 Mar 23	976	-1,115	490	0
31 Dec 22	933	-703	451	0
30 Sep 22	876	-716	409	0
30 Jun 22	835	-507	365	0
31 Mar 22	766	-357	283	0
31 Dec 21	702	-419	283	0
30 Sep 21	646	-486	291	0
30 Jun 21	600	-634	305	0
31 Mar 21	573	-704	306	0
31 Dec 20	540	-554	318	0
30 Sep 20	495	-601	313	0
30 Jun 20	450	-530	313	0
31 Mar 20	407	-656	307	0
31 Dec 19	381	-715	285	0
30 Sep 19	365	-620	268	0
30 Jun 19	345	-570	245	0
31 Mar 19	323	-403	227	0
31 Dec 18	301	-362	208	0
30 Sep 18	274	-245	178	0
30 Jun 18	241	-216	153	0
31 Mar 18	203	-170	133	0
31 Dec 17	155	-51	123	166
30 Sep 17	103	-115	105	0
30 Jun 17	57	-124	99	0
31 Mar 17	22	-123	87	0
31 Dec 16	5	-267	81	0
30 Sep 16	1	-243	85	0
30 Jun 16	1	-239	78	0
31 Mar 16	1	-218	73	0
31 Dec 15	1	-220	66	0
30 Sep 15	0	-200	55	0

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/08/23 02:06
Gün Sonu Hisse Fiyatı	2026/08/21 00:00
Kazançlar	2026/06/30
Yıllık Kazançlar	2025/12/31

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

Analist	Kurum
Brian Skorney	Baird
Huidong Wang	Barclays
Eliana Merle	Barclays

Sarepta Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2026 earnings released: US$0.046 loss per share (vs US$2.01 profit in 2Q 2025)

Sarepta Therapeutics, Inc. to Report Q2, 2026 Results on Aug 05, 2026

First quarter 2026 earnings released: EPS: US$3.15 (vs US$4.60 loss in 1Q 2025)

Sarepta Therapeutics, Inc. to Report Q1, 2026 Results on May 06, 2026

Full year 2025 earnings released: US$7.13 loss per share (vs US$2.47 profit in FY 2024)

Sarepta Therapeutics, Inc. to Report Q4, 2025 Results on Feb 25, 2026

Recent updates

New major risk - Revenue and earnings growth

Sarepta Therapeutics, Inc. Revises Revenue Guidance for the Year 2026

Second quarter 2026 earnings released: US$0.046 loss per share (vs US$2.01 profit in 2Q 2025)

Sarepta Therapeutics, Inc. Announces Board Changes, Effective July 28, 2026

Sarepta Therapeutics, Inc. Announces CEO Changes, Effective July 28, 2026

Sarepta Therapeutics, Inc. to Report Q2, 2026 Results on Aug 05, 2026

Investor sentiment improves as stock rises 16%

Sarepta Therapeutics Announces FDA Acceptance Of Supplemental New Drug Applications For Amondys 45 And Vyondys 53 For Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from Russell 1000 Index

Investor sentiment improves as stock rises 15%

Investor sentiment deteriorates as stock falls 16%

New major risk - Revenue and earnings growth

First quarter 2026 earnings released: EPS: US$3.15 (vs US$4.60 loss in 1Q 2025)

Sarepta Therapeutics, Inc., Annual General Meeting, Jun 04, 2026

Sarepta Therapeutics, Inc. to Report Q1, 2026 Results on May 06, 2026

Sarepta Therapeutics Announces First Clinical Data from Sirna Pipeline Targeting FSHD1 and DM1

Sarepta Therapeutics Provides Regulatory Update On Amondys 45 And Vyondys 53

Sarepta Announces That Screening and Enrollment Are Underway in Endeavor Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of Elevidys Gene Therapy for Non-Ambulant Individuals with Duchenne

Full year 2025 earnings released: US$7.13 loss per share (vs US$2.47 profit in FY 2024)

Douglas Ingram Plans to Retire as Chief Executive Officer of Sarepta Therapeutics, Inc

Sarepta Therapeutics, Inc. Announces Commercial Launch of ELEVIDYS in Japan

Sarepta Therapeutics, Inc. to Report Q4, 2025 Results on Feb 25, 2026

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease

Sarepta Therapeutics, Inc. Announces Positive Topline Three-Year EMBARK Results Showing EleVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

Sarepta Therapeutics, Inc. Announces Submission of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease

President & COO recently sold €250k worth of stock

Sarepta Therapeutics, Inc. Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of Elevidys Gene Therapy for Non-Ambulant Individuals with Duchenne

Sarepta Provides Progress Update for Srp-1003, Its Investigational Sirna Treatment for Myotonic Dystrophy Type 1

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

Third quarter 2025 earnings released: US$1.80 loss per share (vs US$0.35 profit in 3Q 2024)

Sarepta Therapeutics Announces Completion of Its Confirmatory Study, ESSENCE

Sarepta Therapeutics, Inc. to Report Q3, 2025 Results on Nov 03, 2025

Sarepta Therapeutics, Inc. announced that it expects to receive $20 million in funding from J. Wood Capital Advisors LLC

Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm

Sarepta Therapeutics, Inc. to Report Q2, 2025 Results on Aug 06, 2025

FDA Informs Sarepta Therapeutics, Inc. to Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals with Duchenne Muscular Dystrophy

Sarepta Therapeutics Acknowledges CHMP Negative Opinion for Eletidys in the European Union

Sarepta Therapeutics, Inc. Announces Voluntary Pause of Eletidys Shipments in the U.S

Sarepta Therapeutics, Inc Announces Workforce Reduction Due to Strategic Restructuring

Now 29% overvalued

U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta's Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4

Sarepta Therapeutics, Inc. Provides Update on UK Dosing in ENVISION Study of Eletidys for the Treatment of Duchenne Muscular Dystrophy

New major risk - Financial position

Sarepta Therapeutics, Inc. Shares New Protein Expression and Safety Results from Endeavor in Participants 2 Years Old At Time of Treatment

Sarepta Therapeutics, Inc. Announces Approval in Japan of ELEVIDYS, A Gene Therapy to Treat Duchenne Muscular Dystrophy

Insufficient new directors

Sarepta Therapeutics, Inc. Revises Earnings Guidance for 2025

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi

Endüstri ve Sektör Metrikleri

Analist Kaynakları